Impact of HbA1c, followed from onset of type 1 diabetes, on the development of severe retinopathy and nephropathy: The viss study (vascular diabetic complications in Southeast Sweden)

Diabetes Care

Volumn 38, Issue 2, 2015, Pages 308-315

  Nordwall, Maria ^a   Abrahamsson, Mariann ^a   Dhir, Meryl ^a   Fredrikson, Mats ^a   Ludvigsson, Johnny ^a   Arnqvist, Hans J ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN A1C; INSULIN; TRIACYLGLYCEROL; GLYCOSYLATED HEMOGLOBIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DISEASE SEVERITY; EYE EXAMINATION; EYE PHOTOGRAPHY; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; LONGITUDINAL STUDY; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; POPULATION RESEARCH; PREVALENCE; PROLIFERATIVE RETINOPATHY; PROTEIN ANALYSIS; PROTEIN FUNCTION; SWEDEN; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; VERY ELDERLY; ADOLESCENT; BLOOD; CHILD; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; METABOLISM; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHILD; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DIABETIC RETINOPATHY; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INCIDENCE; MALE; MIDDLE AGED; SWEDEN; YOUNG ADULT;

EID: 84921915556     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc14-1203     Document Type: Article

References (40)

1. Bunn HF, Gabbay KH, Gallop PM. The glycosylation of hemoglobin: relevance to diabetes mellitus. Science 1978;200:21-27
2. Lyons TJ. Glycation and oxidation: a role in the pathogenesis of atherosclerosis. Am J Cardiol 1993;71:26B-31B
3. Dahl-Jørgensen K, Brinchmann-Hansen O, Hanssen KF, et al. Effect of near normoglycaemia for two years on progression of early diabetic retinopathy, nephropathy, and neuropathy: the Oslo study. Br Med J (Clin Res Ed) 1986;293:1195-1199
4. Reichard P, Pihl M, Rosenqvist U, Sule J. Complications in IDDM are caused by elevated blood glucose level: the Stockholm Diabetes Intervention Study (SDIS) at 10-year follow up. Diabetologia 1996;39:1483-1488
5. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetesmellitus. N Engl JMed 1993;329:977-986
6. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-412
7. Bojestig M, Arnqvist HJ, Hermansson G, Karlberg BE, Ludvigsson J. Declining incidence of nephropathy in insulin-dependent diabetes mellitus. N Engl J Med 1994;330:15-18
8. Nordwall M, Bojestig M, Arnqvist HJ, Ludvigsson J; Linköping Diabetes Complications Study. Declining incidence of severe retinopathy and persisting decrease of nephropathy in an unselected population of Type 1 diabetes-the Linköping Diabetes Complications Study. Diabetologia 2004;47:1266-1272
9. Nordwall M, Arnqvist HJ, Bojestig M, Ludvigsson J. Good glycemic control remains crucial in prevention of late diabetic complicationsdthe Linköping Diabetes Complications Study. Pediatr Diabetes 2009;10:168-176
10. Krolewski AS, Warram JH, Rand LI, Kahn CR. Epidemiologic approach to the etiology of type I diabetes mellitus and its complications. N Engl J Med 1987;317:1390-1398
11. Kofoed-Enevoldsen A, Borch-Johnsen K, Kreiner S, Nerup J, Deckert T. Declining incidence of persistent proteinuria in type I (insulindependent) diabetic patients in Denmark. Diabetes 1987;36:205-209
12. Kullberg CE, Abrahamsson M, Arnqvist HJ, Finnström K, Ludvigsson J; VISS Study Group. Prevalence of retinopathy differs with age at onset of diabetes in a population of patients with Type 1 diabetes. Diabet Med 2002;19:924-931
13. Porta M, Dalmasso P, Grassi G, et al. Prepubertal onset of type 1 diabetes and appearance of retinopathy. Diabetes Metab 2004;30:229-233
14. Laakso M, Cederberg H. Glucose control in diabetes: which target level to aim for? J Intern Med 2012;272:1-12
15. Fullerton B, Jeitler K, Seitz M, Horvath K, Berghold A, Siebenhofer A. Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus. Cochrane Database Syst Rev 2014;2:CD009122
16. Hoelzel W, Weykamp C, Jeppsson JO, et al.; IFCC Working Group on HbA1c Standardization. IFCC reference systemfor measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study. Clin Chem 2004;50:166-174
17. Kullberg CE, Bergström A, Dinesen B, et al. Comparisons of studies on diabetic complications hampered by differences in GHb measurements. Diabetes Care 1996;19:726-729
18. Treviño G. Consensus statement on the Worldwide Standardization of the Hemoglobin A1C Measurement: the American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and Laboratory Medicine, and the International Diabetes Federation: response to the Consensus Committee. Diabetes Care 2007;30:e141
19. Matthews JN, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. BMJ 1990;300:230-235
20. Diabetic retinopathy study. Report Number
21. Design, methods, and baseline results. Report Number 7. A modification of the Airlie House classification of diabetic retinopathy. Prepared by the Diabetic Retinopathy. Invest Ophthalmol Vis Sci 1981;21:1-226
22. Bojestig M, Arnqvist HJ, Karlberg BE, Ludvigsson J. Glycemic control and prognosis in type I diabetic patients with microalbuminuria. Diabetes Care 1996;19:313-317
23. Feldt-Rasmussen B, Mathiesen ER, Jensen T, Lauritzen T, Deckert T. Effect of improved metabolic control on loss of kidney function in type 1 (insulin-dependent) diabetic patients: an update of the Steno studies. Diabetologia 1991;34:164-170
24. The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes 1996;45:1289-1298
25. Danne T, Weber B, Hartmann R, Enders I, Burger W, Hovener G. Long-term glycemic control has a nonlinear association to the frequency of background retinopathy in adolescents with diabetes. Follow-up of the Berlin Retinopathy Study. Diabetes Care 1994;17:1390-1396
26. Krolewski AS, Laffel LM, Krolewski M, Quinn M, Warram JH. Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus. N Engl J Med 1995;332:1251-1255
27. Warram JH, Manson JE, Krolewski AS. Glycosylated hemoglobin and the risk of retinopathy in insulin-dependent diabetes mellitus. N Engl J Med 1995;332:1305-1306
28. White NH, Sun W, Cleary PA, et al. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Arch Ophthalmol 2008;126:1707-1715
29. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000;342:381-389
30. Hirose A, Furushima D, Yamaguchi N, Kitano S, Uchigata Y. Prediction of retinopathy at 20 years after onset in younger-onset type 1 diabetes using mean metabolic memory-free HbA1c values: the importance of using HbA1c data of total, not partial, diabetes duration. Diabetes Care 2013;36:3812-3814
31. Rossing P, Hommel E, Smidt UM, Parving HH. Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment. Diabetologia 1994;37:511-516
32. Chaturvedi N, Porta M, Klein R, et al.; DIRECT Programme Study Group. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet 2008;372:1394-1402
33. Lv J, Perkovic V, Foote CV, Craig ME, Craig JC, Strippoli GF. Antihypertensive agents for preventing diabetic kidney disease. Cochrane Database Syst Rev 2012;12:CD004136
34. Mauer M, Zinman B, Gardiner R, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009;361:40-51
35. Harindhanavudhi T, Mauer M, Klein R, Zinman B, Sinaiko A, Caramori ML; Renin Angiotensin System Study (RASS) group. Benefits of Renin-Angiotensin blockade on retinopathy in type 1 diabetes vary with glycemic control. Diabetes Care 2011;34:1838-1842
36. Matikainen N, Kahri J, Taskinen MR. Reviewing statin therapy in diabetesdtowards the best practise. Prim Care Diabetes 2010;4:9-15
37. Leiter LA. The prevention of diabetic microvascular complications of diabetes: is there a role for lipid lowering? Diabetes Res Clin Pract 2005;68(Suppl. 2):S3-S14
38. Andersen AR, Christiansen JS, Andersen JK, Kreiner S, Deckert T. Diabetic nephropathy in Type 1 (insulin-dependent) diabetes: an epidemiological study. Diabetologia 1983;25:496-501
39. Groop PH, Thomas MC, Moran JL, et al.; FinnDiane Study Group. The presence and severity of chronic kidney disease predicts allcause mortality in type 1 diabetes. Diabetes 2009;58:1651-1658
40. Rosolowsky ET, Skupien J, Smiles AM, et al. Risk for ESRD in type 1 diabetes remains high despite renoprotection. J Am Soc Nephrol 2011;22:545-553